BioCentury | Jan 12, 2021
Product Development
Mesoblast to seek advancement of heart failure cell therapy on 60% composite CV outcomes reduction
...heart failure. Behind Revascor are AZD4831, an MPO...
...steroid-refractory graft-versus-host disease and ARDS.TARGETSMPO – Myeloperoxidase (MPO)NLR...
...steroid-refractory graft-versus-host disease and ARDS.TARGETSMPO – Myeloperoxidase (MPO)NLR...